Log In
BCIQ
Print this Print this
 

CGF166

  Manage Alerts
Collapse Summary General Information
Company GenVec Inc.
DescriptionRecombinant adenovirus 5 (Ad5) vector containing a cDNA carrying the atonal homolog 1 (ATOH1; HATH1) transcription factor delivered via intra-labyrinthine infusion
Molecular Target Atonal homolog 1 (ATOH1) (HATH1)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adenovirus
Latest Stage of DevelopmentPhase I/II
Standard IndicationHearing loss
Indication DetailsTreat hearing loss
Regulatory Designation
PartnerNovartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$7.0M

$206.6M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/25/2010

Undisclosed

$7.0M

$206.6M

Get a free BioCentury trial today